• Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

    • August 27, 2019
    • Posted By : admin
    • 0 Comment
    •   31 views

    Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.

    Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC).

    Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The POTELLIGENT® technology generates antibodies with enhanced antibody dependent cellular cytotoxicity (ADCC). The investigational antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signaling. CAN04 is currently produced in a Chinese Hamster Ovary (CHO) cell line provided by BioWa which has been engineered using POTELLIGENT® Technology. The extended agreement enables Cantargia to create and use additional CHO cell lines engineered using POTELLIGENT® Technology and develop and commercialize CAN04 made through such CHO cell line.

  31 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!